Chicago Partners Investment Group LLC Has $598,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Chicago Partners Investment Group LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,850 shares of the biopharmaceutical company’s stock after purchasing an additional 540 shares during the period. Chicago Partners Investment Group LLC’s holdings in Gilead Sciences were worth $598,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Sumitomo Life Insurance Co. raised its position in Gilead Sciences by 0.7% in the third quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock worth $1,494,000 after purchasing an additional 117 shares in the last quarter. Sivia Capital Partners LLC raised its position in Gilead Sciences by 3.9% in the third quarter. Sivia Capital Partners LLC now owns 3,249 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 123 shares in the last quarter. Roberts Wealth Advisors LLC raised its position in Gilead Sciences by 1.9% in the third quarter. Roberts Wealth Advisors LLC now owns 7,035 shares of the biopharmaceutical company’s stock worth $599,000 after purchasing an additional 130 shares in the last quarter. Wagner Wealth Management LLC raised its position in Gilead Sciences by 1.7% in the third quarter. Wagner Wealth Management LLC now owns 8,026 shares of the biopharmaceutical company’s stock worth $673,000 after purchasing an additional 135 shares in the last quarter. Finally, Institute for Wealth Management LLC. raised its position in Gilead Sciences by 1.9% in the second quarter. Institute for Wealth Management LLC. now owns 7,551 shares of the biopharmaceutical company’s stock worth $518,000 after purchasing an additional 142 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock worth $3,033,340 over the last ninety days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.4 %

Shares of NASDAQ GILD opened at $89.84 on Tuesday. The company’s 50 day simple moving average is $84.05 and its 200 day simple moving average is $74.38. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $90.71. The firm has a market capitalization of $111.85 billion, a P/E ratio of 109.56, a P/E/G ratio of 3.09 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. On average, analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on GILD shares. Truist Financial increased their price target on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Wells Fargo & Company raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $78.00 to $100.00 in a research note on Monday, October 7th. Piper Sandler reaffirmed an “overweight” rating and set a $95.00 price objective on shares of Gilead Sciences in a research note on Wednesday, September 11th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 price objective on shares of Gilead Sciences in a research note on Monday, September 16th. Finally, Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective on the stock. Ten investment analysts have rated the stock with a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $86.85.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.